These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 21029028

  • 1. New delivery strategies for the old pentavalent antimonial drugs.
    Frézard F, Demicheli C.
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1343-58. PubMed ID: 21029028
    [Abstract] [Full Text] [Related]

  • 2. Intradermal treatment of cutaneous leishmaniasis with two antimonial drugs.
    Morsy TA, Essa MH, Aboul Anaan AM, Montasser MF.
    J Egypt Soc Parasitol; 1988 Jun; 18(1):341-4. PubMed ID: 2836525
    [No Abstract] [Full Text] [Related]

  • 3. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Ribera E, Ocaña I, de Otero J, Cortes E, Gasser I, Pahissa A.
    Am J Med; 1996 May; 100(5):496-501. PubMed ID: 8644760
    [Abstract] [Full Text] [Related]

  • 4. [Cutaneous leishmaniasis].
    Vion B.
    Rev Med Suisse Romande; 1989 Jun; 109(6):443-9. PubMed ID: 2547241
    [No Abstract] [Full Text] [Related]

  • 5. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 6. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis.
    Berhe N, Abraham Y, Hailu A, Ali A, Mengistu G, Tsige K, Abebe Y.
    East Afr Med J; 2001 Nov; 78(11):608-10. PubMed ID: 12219968
    [Abstract] [Full Text] [Related]

  • 7. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
    Borborema SE, Schwendener RA, Osso JA, de Andrade HF, do Nascimento N.
    Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
    [Abstract] [Full Text] [Related]

  • 8. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
    Bogenrieder T, Lehn N, Landthaler M, Stolz W.
    Dermatology; 2003 Oct; 206(3):269-72. PubMed ID: 12673089
    [Abstract] [Full Text] [Related]

  • 9. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
    Amusategui I, Sainz A, Tesouro MA.
    Ann N Y Acad Sci; 1998 Jun 29; 849():444-6. PubMed ID: 9668509
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of cutaneous leishmaniasis in travelers 2009.
    Blum JA, Hatz CF.
    J Travel Med; 2009 Jun 29; 16(2):123-31. PubMed ID: 19335813
    [No Abstract] [Full Text] [Related]

  • 11. [Cutaneous leishmaniasis].
    Enk CD, Gardlo K, Hochberg M, Ingber A, Ruzicka T.
    Hautarzt; 2003 Jun 29; 54(6):506-12. PubMed ID: 12759734
    [Abstract] [Full Text] [Related]

  • 12. Drug hypersensitivity syndrome induced by meglumine antimoniate.
    Jeddi F, Caumes E, Thellier M, Jauréguiberry S, Mazier D, Buffet PA.
    Am J Trop Med Hyg; 2009 Jun 29; 80(6):939-40. PubMed ID: 19478253
    [Abstract] [Full Text] [Related]

  • 13. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ, Aminjavaheri M.
    Eur J Dermatol; 2003 Jun 29; 13(1):40-3. PubMed ID: 12609780
    [Abstract] [Full Text] [Related]

  • 14. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
    Demicheli C, Ochoa R, da Silva JB, Falcão CA, Rossi-Bergmann B, de Melo AL, Sinisterra RD, Frézard F.
    Antimicrob Agents Chemother; 2004 Jan 29; 48(1):100-3. PubMed ID: 14693525
    [Abstract] [Full Text] [Related]

  • 15. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
    Sadeghian G, Nilforoushzadeh MA.
    Int J Dermatol; 2006 Jul 29; 45(7):819-21. PubMed ID: 16863518
    [Abstract] [Full Text] [Related]

  • 16. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec 29; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of localized cutaneous leishmaniasis].
    Buffet P, Caumes E, Gentilini M.
    Ann Dermatol Venereol; 1994 Dec 29; 121(6-7):503-11. PubMed ID: 7702288
    [No Abstract] [Full Text] [Related]

  • 18. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S, Marr JJ.
    N Engl J Med; 1992 Mar 12; 326(11):741-4. PubMed ID: 1738379
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
    Chulay JD, Fleckenstein L, Smith DH.
    Trans R Soc Trop Med Hyg; 1988 Mar 12; 82(1):69-72. PubMed ID: 2845611
    [Abstract] [Full Text] [Related]

  • 20. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B, Abbaszadeh B, Khamesipour A.
    Eur J Dermatol; 2005 Mar 12; 15(2):85-7. PubMed ID: 15757817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.